{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "A53T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "‘a-synuclein aggregation is a major event in the development of Lewy body pathology.’",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that a-synuclein aggregation is a key event in the development of Lewy body pathology, directly relating to Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "‘recombinant a-synuclein can aggregate to form amyloid fibrils that resemble Lewy bodies’",
          "judgment": "Yes",
          "reasoning": "The text describes an assay – recombinant a-synuclein aggregation – that models a key feature of the disease (Lewy body formation).",
          "next_step_or_outcome": "Proceed to Step 3"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The A53T mutation directly promotes a-synuclein aggregation, a key feature in Lewy body formation and, therefore, the pathogenesis of Parkinson's disease. The assay is a relevant model for this process and a robust study demonstrates a correlation of the mutation with the disease."
    }
  ]
}